Summit’s ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds.
Summit Therapeutics’ Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
